Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Type

Type

Guidance programme 1 selected

Guidance programme

Showing 1 to 10 of 41

TitleReference numberPublishedLast updated
Trastuzumab deruxtecan for treating hormone receptor-positive HER2-low metastatic breast cancer after 2 or more endocrine treatments (terminated appraisal)TA1112
Sacituzumab govitecan for treating hormone receptor-positive HER2-negative metastatic breast cancer after 2 or more treatments (terminated appraisal)TA1089
Ribociclib with an aromatase inhibitor for adjuvant treatment of hormone receptor-positive HER2-negative early breast cancer at high risk of recurrenceTA1086
Capivasertib with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatmentTA1063
Olaparib for treating BRCA mutation-positive HER2-negative advanced breast cancer after chemotherapyTA1040
Elacestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer with an ESR1 mutation after endocrine treatmentTA1036
Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapyTA992
Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutationsTA952
Olaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapyTA886
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatmentsTA862

Results per page

  1. 10
  2. 25
  3. 50
  4. All